NZ764565B2 - Nano-particles that contain synthetic variants of gm3 ganglioside as adjuvants in vaccines - Google Patents
Nano-particles that contain synthetic variants of gm3 ganglioside as adjuvants in vaccines Download PDFInfo
- Publication number
- NZ764565B2 NZ764565B2 NZ764565A NZ76456518A NZ764565B2 NZ 764565 B2 NZ764565 B2 NZ 764565B2 NZ 764565 A NZ764565 A NZ 764565A NZ 76456518 A NZ76456518 A NZ 76456518A NZ 764565 B2 NZ764565 B2 NZ 764565B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- ganglioside
- group
- adjuvant
- synthetic variants
- ceramide
- Prior art date
Links
- 239000002671 adjuvant Substances 0.000 title claims abstract 11
- 239000002105 nanoparticle Substances 0.000 title claims abstract 5
- 229960005486 vaccine Drugs 0.000 title claims abstract 4
- 150000002270 gangliosides Chemical class 0.000 title 1
- -1 GM3 ganglioside Chemical class 0.000 claims abstract 9
- 239000000427 antigen Substances 0.000 claims abstract 6
- 102000036639 antigens Human genes 0.000 claims abstract 6
- 108091007433 antigens Proteins 0.000 claims abstract 6
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims abstract 5
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims abstract 5
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims abstract 5
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims abstract 5
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims abstract 5
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims abstract 5
- 239000005642 Oleic acid Substances 0.000 claims abstract 5
- 235000021355 Stearic acid Nutrition 0.000 claims abstract 5
- 229940106189 ceramide Drugs 0.000 claims abstract 5
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims abstract 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract 5
- 229930195729 fatty acid Natural products 0.000 claims abstract 5
- 239000000194 fatty acid Substances 0.000 claims abstract 5
- 150000004665 fatty acids Chemical class 0.000 claims abstract 5
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims abstract 5
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims abstract 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims abstract 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims abstract 5
- 102000004169 proteins and genes Human genes 0.000 claims abstract 5
- 108090000623 proteins and genes Proteins 0.000 claims abstract 5
- 239000008117 stearic acid Substances 0.000 claims abstract 5
- 239000006185 dispersion Substances 0.000 claims abstract 4
- 230000002209 hydrophobic effect Effects 0.000 claims abstract 4
- 239000012528 membrane Substances 0.000 claims abstract 4
- 241000588650 Neisseria meningitidis Species 0.000 claims abstract 3
- 239000000203 mixture Substances 0.000 claims abstract 3
- 230000024932 T cell mediated immunity Effects 0.000 claims abstract 2
- 230000028996 humoral immune response Effects 0.000 claims abstract 2
- 102000001301 EGF receptor Human genes 0.000 claims 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 3
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 3
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 241000588653 Neisseria Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 229940037003 alum Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 231100000590 oncogenic Toxicity 0.000 claims 1
- 230000002246 oncogenic effect Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001144—Hormones, e.g. calcitonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
This invention describes how to obtain nano-particulate adjuvants formed by different synthetic variants of the GM3 ganglioside. Depending on the fine structure of the fatty acid in the ceramide of the synthetic GM3, it is possible to obtain adjuvants for the specific and specialised stimulation of the humoral or cellular immune response against accompanying antigens. In particular, the invention provides immunogenic vaccine compositions that comprise peptides, polypeptides or proteins and the aforementioned nanoparticles, which are formed through the dispersion of hydrophobic proteins of the outer membrane complex (OMC) of Neisseria meningitidis with fully synthetic variants of the GM3 ganglioside wherein the fatty acid in the ceramide of the GM3 ganglioside is selected from the group consisting of stearic acid (18:0) and oleic acid (18:1).
Claims (7)
1.CLAIMS 5 1. An adjuvant that comprises nanoparticles comprising a dispersion of hydrophobic proteins of the outer membrane complex of the bacterium Neisseria meningitidis in a solution and fully synthetic variants of GM3 ganglioside wherein the fatty acid in the ceramide of the GM3 ganglioside is selected from the group consisting of stearic acid (18:0) and oleic acid (18:1). 10 2. A vaccine composition that comprises one of the nano-particulated adjuvants of claim 1 and an antigen selected from the group comprising: - the growth factor receptors HER1, HER2, HER3 alone or in combination, and
2.- GmRHm1-TTpeptide.
3. The vaccine composition of claim 2 which optionally comprises another adjuvant 15 selected from the group comprising: - alum and - an oily adjuvant.
4. Use of an adjuvant that comprises nanoparticles comprising a dispersion of hydrophobic proteins of the outer membrane complex of the bacterium Neisseria 20 meningitidis in a solution and fully synthetic variants of GM3 ganglioside wherein the fatty acid in the ceramide of the GM3 ganglioside is selected from the group consisting of stearic acid (18:0) and oleic acid (18:1) and an antigen selected from the group consisting of: - the growth factor receptors HER1, HER2, HER3 alone or in combination, and 25 - GmRHm1-TTpeptide in the manufacture of a medicament for the treatment of cancer.
5. The use of an adjuvant that comprises nanoparticles comprising a dispersion of hydrophobic proteins of the outer membrane complex of the bacterium Neisseria meningitidis in a solution and fully synthetic variants of GM3 ganglioside wherein the 30 fatty acid in the ceramide of the GM3 ganglioside is selected from the group consisting of stearic acid (18:0) and oleic acid (18:1) and an antigen selected from the group consisting of: - the growth factor receptors HER1, HER2, HER3 alone or in combination, and - GmRHm1-TTpeptide in the manufacture of a medicament for the treatment of chronic 35 viral infections with oncogenic viruses.
6. The use of claim 4 or 5 wherein the adjuvant comprises stearic acid (18:0) to stimulate the antigen-specific humoral immune response.
7. The use of claim 4 or 5 wherein the adjuvant comprises oleic acid (18:1) to stimulate the antigen-specific cellular immune response.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2017000137A CU24534B1 (en) | 2017-11-06 | 2017-11-06 | NANO-PARTICULATE ADJUVANTS CONTAINING SYNTHETIC VARIANTS OF GM3 GANGLIOSIDE |
| PCT/CU2018/050003 WO2019086056A1 (en) | 2017-11-06 | 2018-10-24 | Nano-particles that contain synthetic variants of gm3 ganglioside as adjuvants in vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ764565A NZ764565A (en) | 2024-02-23 |
| NZ764565B2 true NZ764565B2 (en) | 2024-05-24 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Abbaraju et al. | Asymmetric mesoporous silica nanoparticles as potent and safe immunoadjuvants provoke high immune responses | |
| Mahony et al. | In vivo delivery of bovine viral diahorrea virus, E2 protein using hollow mesoporous silica nanoparticles | |
| EP3556353A3 (en) | Lipid nanoparticle vaccine adjuvants and antigen delivery systems | |
| EP3760225A3 (en) | Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancers | |
| MX363529B (en) | Outer membrane vesicles. | |
| Lim | Vaccine adjuvant materials for cancer immunotherapy and control of infectious disease | |
| WO2015193359A3 (en) | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll) | |
| EP4397676A3 (en) | Novel peptides and combination of peptides for use in immunotherapy against various tumors | |
| WO2006071983A3 (en) | Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines | |
| WO2014036345A3 (en) | Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins | |
| CR20210066A (en) | NEW PEPTIDES AND SUPPORT STRUCTURES FOR USE IN IMMUNOTHERAPY AGAINST EPIDERMOID CARCINOMA OF THE HEAD AND NECK AND OTHER CANCER (Divisional 2019-0094) | |
| WO2005007673A3 (en) | Immunogenic peptides | |
| US20240075128A1 (en) | Immunogenic constructs, compositions, and methods for inducing immune response | |
| PH12014501795A1 (en) | Rota virus subunit vaccines and methods of making and use thereof | |
| WO2016038625A3 (en) | Superior human papilloma virus antigens with superior immunological properties and vaccine containing it | |
| EA202091116A1 (en) | NANOPARTICLES CONTAINING SYNTHETIC VARIANTS OF GANGLIOSIDE GM3 AS ADJUVANTS IN VACCINES | |
| NZ764565B2 (en) | Nano-particles that contain synthetic variants of gm3 ganglioside as adjuvants in vaccines | |
| EP2899203A3 (en) | Leishmania vaccine using sand fly salivary immunogen | |
| TNSN07187A1 (en) | Immunotherapeutic formulations to generate autoantibodies capable to avoid the binding of interleukin-2 to its receptor. their use in the treatment of cancer | |
| EP4219524A3 (en) | Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers | |
| Virginio et al. | Assessment of the adjuvant activity of mesoporous silica nanoparticles in recombinant | |
| Petrovsky | Focus on influenza vaccines | |
| EA202091864A3 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NON-SMALL CELL LUNG CANCER (NSCLC) AND OTHER TYPES OF CANCER | |
| EA202190241A1 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF CLL AND OTHER TYPES OF CANCER | |
| EA202190465A2 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY NHL AND OTHER TYPES OF CANCER |